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In the present study we have exploited isogenic erg mutants of Saccharomyces cerevisiae to examine the
contribution of an altered lipid environment on drug susceptibilities of yeast cells. It is observed that erg
mutants, which possess high levels of membrane fluidity, were hypersensitive to the drugs tested, i.e., cyclo-
heximide (CYH), o-phenanthroline, sulfomethuron methyl, 4-nitroquinoline oxide, and methotrexate. Most of
the erg mutants except mutant erg4 were, however, resistant to fluconazole (FLC). By using the fluorophore
rhodamine-6G and radiolabeled FLC to monitor the passive diffusion, it was observed that erg mutant cells
elicited enhanced diffusion. The addition of a membrane fluidizer, benzyl alcohol (BA), to S. cerevisiae wild-type
cells led to enhanced membrane fluidity. However, a 10 to 12% increase in BA-induced membrane fluidity did
not alter the drug susceptibilities of the S. cerevisiae wild-type cells. The enhanced diffusion observed in erg
mutants did not seem to be solely responsible for the observed hypersensitivity of erg mutants. In order to
ascertain the functioning of drug extrusion pumps encoding the genes CDR1 (ATP-binding cassette family) and
CaMDR1 (MFS family) of Candida albicans in a different lipid environment, they were independently expressed
in an S. cerevisiae erg mutant background. While the fold change in drug resistance mediated by CaMDR1
remained the same or increased in erg mutants, susceptibility to FLC and CYH mediated by CDR1 was
increased (decrease in fold resistance). Our results demonstrate that between the two drug extrusion pumps,
Cdr1p appeared to be more adversely affected by the fluctuations in the membrane lipid environment (par-
ticularly to ergosterol). By using 6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino-hexanoyl] sphingosyl phospho-
choline (a fluorescent analogue of sphingomyelin), a close interaction between membrane ergosterol and
sphingomyelin which appears to be disrupted in erg mutants is demonstrated. Taken together it appears that
multidrug resistance in yeast is closely linked to the status of membrane lipids, wherein the overall drug
susceptibility phenotype of a cell appears to be an interplay among drug diffusion, extrusion pumps, and the
membrane lipid environment.
The incidence of the acquisition of resistance to azoles by
Candida albicans cells has increased considerably in recent
years, which has posed serious problems in successful chemo-
therapy of infections caused by such cells. Although the mo-
lecular basis of azole resistance in C. albicans is not very clear,
accumulated evidence suggests that multidrug resistance
(MDR) is a multifactorial phenomenon, with some of the most
common mechanisms being the failure of drug accumulation
mediated by drug extrusion pumps such as CDR1, CDR2
(ATP-binding cassette [ABC] family), and CaMDR1 (MFS
family), alterations in Erg11p, and upregulation of ERG11. A
combination of different resistance mechanisms has been re-
ported to be responsible for fluconazole (FLC) resistance in
clinical isolates of C. albicans (31, 41, 42, 44). Recent evidence
also suggests that the generation of a resistant strain from a
highly susceptible strain is the result of multiple mechanisms,
each of which probably contributes partially to the resistant
phenotype (23, 52). Of note, other mechanisms like the role of
5,6-desaturase (ERG3), 22-desaturase (ERG5), chromo-
somal alterations, modification of drugs, and membrane lipid
composition which have been found to affect azole susceptibil-
ities also merit consideration (21, 22, 27, 35, 37, 39).
On the basis of the results of several studies, a close inter-
action between membrane lipids and drug extrusion pump
proteins has been realized (6, 7, 11, 45). On the one hand, it
has been observed that the MDR ABC protein of mammalian
cells (P glycoprotein [P-gp]) and MDR proteins of yeasts
(Pdr5p and Yor1p in Saccharomyces cerevisiae and Cdr1p and
Cdr2p in C. albicans) can translocate phospholipids between
the two monolayers of the plasma membrane, while on the
other hand P-gp has been shown to participate in sterol ho-
meostasis in mammalian cells (5, 34). Additionally, these drug
extrusion pumps are found to be particularly sensitive to the
nature and the physical state of the surrounding lipids (11, 19,
47).
That lipid could also play an important role in azole suscep-
tibilities is becoming apparent from a host of recent studies. It
has been shown that some of the azole-resistant C. albicans
isolates exhibit altered membrane phospholipid and sterol
compositions (15, 23, 30). Such lipid changes are observed both
in clinical and in in vitro-adapted azole-resistant isolates of C.
albicans (16, 17, 23, 30). We as well as others have observed
that Cdr1p and Pdr5p are sensitive to fluctuations in the lipid
environment, where functions mediated by these drug extru-
sion pumps are selectively affected (19, 47). Taken together, it
appears that the associated changes in membrane lipid com-
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position (phospholipid and ergosterol), its order (fluidity), and
asymmetry could be important determinants in the drug sus-
ceptibilities of yeast cells.
In order to study the contribution of membrane lipids in
drug susceptibilities, in the present study we have exploited
isogenic erg mutants of S. cerevisiae that, owing to blocks in
different steps of ergosterol biosynthesis, possess increased
levels of fluid membranes. We have also expressed two drug
extrusion pumps, i.e., Cdr1p and CaMdr1p, in erg mutants to
compare their functioning in an altered lipid environment (13,
43). We observed that erg mutants which possess higher levels
of membrane fluidity were hypersensitive to the drugs tested.
erg mutant cells elicit enhanced diffusion of drugs; however,
that does not seem to solely affect drug susceptibilities. Fur-
thermore, our results suggest that between the two pump pro-
teins, Cdr1p, when it is expressed in erg mutants of S. cerevisiae,
interacts more intimately with membrane lipids, particularly
with ergosterol and sphingolipid, and thus is more severely
affected by lipid perturbations.
MATERIALS AND METHODS
Materials. Medium chemicals were obtained from Difco (Detroit, Mich.) and
HiMedia (Mumbai, India). Labeled 6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl) ami-
no-hexanoyl] sphingosyl phosphocholine (NBD-sphingomyelin [NBD-SM]) was
purchased from Molecular Probes (Eugene, Oreg.), lipid N-rhodamine-dioleoyl
phosphatidylethanolamine (N-Rh-DOPE) was purchased from Avanti Polar Lip-
ids Inc. (Albaster, Ala), and L-dipalmitoyl-phosphatidylcholine (L-DPPC) was
obtained from Sigma Chemical Co. (St. Louis, Mo.). The drugs cycloheximide
(CYH), o-phenanthroline (PHE), 4-nitroquinoline oxide (4-NQO), and metho-
trexate (MTX) were from Sigma Chemical Co. FLC and sulfomethuron methyl
(SMM) were provided as gifts by Pfizer (Sandwich, United Kingdom) and Du-
pont (Wilmington, Del.), respectively.
Strains used in this study. Wild-type (WT) S. cerevisiae strain ABC287 (Mat
ura3-52 leu21 lys2-801 his3200 pep4::HIS3 prb11.6R can1) and isogenic erg
mutants designated erg2 (strain ABC271; Mat ura3-52 leu21 lys2-801 his3200
pep4::HIS3 prb11.6R can1 erg2::LEU2), erg3 (strain ABC261; Mat ura3-52
leu21 lys2-801 his3200 pep4::HIS3 prb11.6R can1 erg3::LEU2), erg4 (strain
ABC283; Mat ura3-52 leu21 lys2-801 his3200 pep4::HIS3 prb11.6R can1
erg4::LEU2), and erg6 (strain ABC265; Mat ura3-52 leu21 lys2-801 his3200
pep4::HIS3 prb11.6R can1 erg6::LEU2) were used in this study and were kind
gifts from Anand Bachhawat (IMTech, Chandigarh, India) (19). All the S.
cerevisiae strains were transformed with plasmid pNC39 (carrying CaMDR1) and
plasmid pS12 (carrying CDR1), which were obtained from a C. albicans genomic
library, as described earlier (13, 43). Of note, both genes had a common vector
background of pYEUra3. All erg mutants and WT strains of S. cerevisiae were
maintained at 30°C in yeast nutrient broth (YNB) medium containing 2% glu-
cose and the respective auxotrophic supplements (47).
Ergosterol extraction and estimation. Sterols were extracted by the alcoholic
KOH method as described by Arthington-Skaggs et al. (2, 3), in which cells
grown overnight were harvested, washed in sterile water, and boiled for 1 h in
25% alcoholic KOH. The boiled cells were cooled and extracted with petroleum
ether. In order to compare the efficiency of sterol extraction, yeast cells were also
mechanically broken in an MSK homogenizer (Braun, Kronberg, Germany)
prior to the sterol extraction. The homogenate was collected, and the sterols
were extracted as described previously (2). An aliquot of sterol extract obtained
by each protocol was diluted fivefold in petroleum ether and scanned spectro-
photometrically between 200 and 320 nm (300 BIO UV-VIS spectrophotometer;
Varian, Victoria, Australia). Both ergosterol and 24(28)-dehydroergosterol
(DHE) absorb at 281.5 nm, whereas only DHE absorbs at 230 nm. The ergos-
terol content was calculated as a percentage of the wet weight of the cell by the
following equations (2): percent ergosterol  percent DHE  [(A281.5/290) 
F]/pellet weight, percent DHE  [(A230/518)  F]/pellet weight, and percent
ergosterol  [percent ergosterol  percent DHE]  percent DHE, where F is
the factor for dilution in petroleum ether, and 290 and 518 are the E values (in
percent per centimeter) determined for crystalline ergosterol and DHE, respec-
tively (2).
Supplementation of yeast cells and erg mutants with ergosterol. For ergosterol
supplementation experiments, cells were grown overnight in the presence of 10
g of ergosterol ml1, which had been dissolved in petroleum ether and added
directly into the medium during inoculation (1). Sterols from supplemented cells
were then extracted and analyzed by recording the wavelength scan between 200
and 320 nm as described above.
Fluorescence polarization studies. The steady-state fluorescence polarization
measurements on yeast cells were carried out essentially as described earlier
(19). Measurements were carried out on whole cells by using a fluorescent probe,
1,6-diphenyl-1,3,5-hexatriene (DPH). Fluorescence polarization was measured
at excitation and emission wavelengths of 360 and 450 nm, respectively. The
measured fluorescence intensities were corrected for background fluorescence
and the light scattering from the unlabeled sample (19).
Drug uptake assay. Passive diffusion of rhodamine-6G (R6G) was determined
essentially by a protocol described previously (23, 51). Approximately 107 cells
from an overnight culture were inoculated in 250 ml of YPD and grown for 5 to
6 h at 30°C. The cells were pelleted and washed three times with phosphate-
buffered saline buffer without glucose (buffer A). The cells were subsequently
resuspended as a 2% cell suspension in deenergization buffer (5 mM dinitro-
phenol and 5 mM 2-deoxy-D-glucose in buffer A) and incubated for 2 h at 30°C.
The cells were then washed; resuspended in buffer A, to which R6G was added
to a final concentration of 10 M; and incubated. An aliquot of 1 ml was taken
at various times and centrifuged at 9,000  g for 2 min. The absorbance of the
supernatant was measured at 527 nm (23). The passive diffusion of FLC was
checked by using radiolabeled [3H]FLC (24, 47). The deenergized cells were
incubated with 100 nM [3H]FLC (0.7 TBq mmol1); and aliquots were removed
at various times, rapidly filtered, and washed three times with ice-cold buffer A
containing an equimolar concentration of cold drug on a Millipore manifold
filtration assembly with 0.45-m-pore-size cellulose nitrate filter disks (Millipore,
Bedford, Mass.). The radioactivity that accumulated in filtered cells and that
adhered to filter disks was measured in a liquid scintillation counter with a
scintillation liquid (Tri-Carb 2900TR; Packard). The radioactivity that adhered
to the filter disk, which was not significant, was subtracted from the experimental
values.
Drug susceptibility testing with S. cerevisiae strains. The susceptibilities of the
yeast isolates (grown in YNB medium containing 2% glucose and the respective
auxotrophic supplements) to FLC, CYH, PHE, SMM, 4-NQO, and MTX were
determined by three different methods. The following stock solutions of the
various drugs were made (the solvent used is given in parentheses): FLC, 1 mg
ml1 (water); CYH, 0.1 mg ml1 (water); PHE, 2 mg ml1 (ethanol); 4-NQO,
0.01 mg ml1 (dimethyl sulfoxide); SMM, 1 mg ml1 (methanol); and MTX, 5
mg ml1 (10 mM Tris-Cl). The resistance to MTX was checked in the presence
of 200 g of sulfanilamide ml1 to deplete the intracellular dihydrofolate reduc-
tase pool, as previously described by Fling et al. (12). The solvents used to
solubilize the different drugs were also tested, and there was no inhibition of
growth due to the solvents used.
(i) Filter disk assay. Yeast cells (105 cells ml1) were mixed with molten agar
(approximately 40°C) and poured in a petri plate. After agar solidification, the
filter disks were placed and the drugs, in a volume of 5 to 10 l, were spotted
onto the disks at the indicated amounts: FLC, 100 g; CYH, 0.5 g; PHE, 20 g;
4-NQO, 2 g; SMM, 5 g; and MTX, 50 g. The plates were incubated at 30°C,
and zones of inhibition were scored after 2 to 3 days (29, 38, 47).
(ii) Microtiter assay. Cells were grown for 48 h at 30°C to obtain single
colonies, which were resuspended in a 0.9% normal saline solution to give an
optical density at 600 nm (OD600) of 0.1. The cells were then diluted 100-fold in
YNB medium containing 2% glucose and the respective auxotrophic supple-
ments. The diluted cell suspensions were added to the wells of round-bottomed
96-well microtiter plates (100 l/well) containing equal volumes of medium (100
l/well) and different concentrations of drugs (23, 50). A drug-free control was
also included. The plates were incubated at 30°C for 48 h. The MIC test end
point was evaluated both by eye and by reading the OD620 in a microplate reader
and is defined as the lowest drug concentration that gave 80% inhibition of
growth compared with the growth of the drug-free controls (the MIC at which
80% of isolates are inhibited [MIC80]).
(iii) Spot assay. The yeast cells were grown overnight on YNB medium
containing 2% glucose and the respective auxotrophic supplements. The cells
were then suspended in normal saline to an OD600 of 0.1 (A600). Five microliters
of fivefold serial dilutions of each yeast culture was spotted onto YNB plates in
the absence (control) and presence of the following drugs: 4-NQO (0.02 g
ml1), CYH (0.01 g ml1), PHE (2 g ml1), SMM (1 g ml1), FLC (8 g
ml1), and MTX (1 g ml1). Growth differences were recorded following
incubation of the plates for 48 h at 30°C. Growth was not affected by the presence
of the solvents used for the drugs (8, 19, 53).
Labeling of cells with NBD-SM. (i) Preparation of donor lipid vesicles. Donor
vesicles containing fluorescent phospholipids were prepared by mixing the de-
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sired proportions of the various phospholipids as described by us and others (20,
48). The typical proportion used was 40 mol% NBD-SM, 2 mol% N-Rh-DOPE,
and 58 mol% L-DPPC. After all of these phospholipids were mixed, chloroform
was evaporated under a stream of N2 to make a thin film and kept overnight
under vacuum desiccation to remove moisture and traces of solvent. Desiccated
phospholipid film was then hydrated by adding 50 mM Tris buffer (pH 7.4; buffer
A) with continuous vortexing. Hydrated membrane film was then sonicated for
30 min under an N2 atmosphere with a water bath sonicator to produce donor
vesicles.
(ii) Labeling of C. albicans cells and erg mutants with NBD-SM. Labeling of
cells with fluorescent lipids was carried out essentially as described earlier (20,
48). Briefly, cells grown to the mid-log phase were harvested by centrifugation at
3,000 rpm for 5 min, washed two times with buffer B, and resuspended (5  109
cells ml1) in the same buffer. Donor vesicles (final concentration, 40 M) were
then added to 900 l of the cell suspension, and every 5 min the fluorescence of
the cell suspension was measured spectrofluorometrically (excitation wavelength,
475 nm; emission wavelength, 525 nm; eclipse spectrofluorometer; Varian) to
check the labeling of the cells by NBD-SM. After 90 min, when labeling of the
cells attained saturation, the labeled cells were washed twice with ice-cold buffer
B and resuspended in 900 l of the same buffer (5  109 cells ml1). Then, fatty
acid-free bovine serum albumin (BSA; final concentration, 2% [wt/vol]) was
added to the cell suspension to allow the back exchange of NBD-SM from the
outer monolayer of the plasma membrane to BSA. At different time intervals,
aliquots of the cell suspension were taken out and centrifuged, and the fluores-
cence in both the supernatant and the pellet was measured. Fluorescence inten-
sities were corrected for background fluorescence in both the supernatant and
the pellet. The BSA-extracted NBD-SM fraction was calculated as follows: per-
cent NBD-SM extracted  (fluorescence of supernatant/total fluorescence from
supernatant and pellet)  100.
RESULTS
S. cerevisiae erg mutant strains lack ergosterol. Mutants with
mutations in the ergosterol biosynthetic pathway do not pro-
duce ergosterol and utilize sterol intermediates to compensate
for the loss of ergosterol (19, 28, 47) (Fig. 1A). To confirm the
FIG. 1. (A) Schematic representation of the late stages of the ergosterol biosynthetic pathway. erg6, erg2, erg3, erg5, and erg4 encode S-adenosyl
methionine methyltransferase, C-8 sterol isomerase, sterol C-5 desaturase, C-22 sterol desaturase, and sterol-24(28) reductase, respectively.
(B) Growth curves of WT (), erg2 (), erg3 (Œ), erg4 (F), and erg6 () strains. The specific growth rates are 1.76 h for WT, 2.01 h for erg2, 1.78 h
for erg3, 1.52 h for erg4, and 1.71 h for erg6. (C) UV absorption spectra of sterols extracted from the S. cerevisiae WT strain and its erg mutants.
Their absorption spectra were recorded as described in Materials and Methods.
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absence of any detectable levels of ergosterol in erg mutant
strains, we compared the absorption spectra of sterols obtained
from an S. cerevisiae WT strain and its isogenic erg mutants
(1–3, 40). The method of Arthington-Skaggs et al. (2, 3) takes
advantage of the unique four-peak spectral absorption pattern
produced by extracted sterols between 240 and 320 nm; this
pattern is indicative of the ergosterol and DHE (a late sterol
pathway intermediate) contents. Both ergosterol and DHE
absorb at 281.5 nm, whereas only DHE shows an intense spec-
tral absorption band at 230 nm. Therefore, the amount of
ergosterol can be determined by calculating the total ergos-
terol plus DHE content (by determination of the amount of
absorption at 281.5 nm) and then subtracting that amount from
the total amount of absorption (at 230 nm) due to DHE only
(2, 3). As evident from Fig. 1C, WT cells gave four character-
istics peaks for ergosterol (no absorption peak at 230 nm)
which were absent for both erg2 and erg3 mutants. Mutant erg6
and erg4 cells, however, gave four characteristic peaks as well
as a strong absorption peak for DHE at 230 nm. Quantitation
of ergosterol from the absorption spectra (see Materials and
Methods) confirmed that the WT strain had an ergosterol
content of 1.3%	 0.07% (expressed as a percentage of the wet
weight of the cells), whereas none of four erg mutants con-
tained ergosterol (data not shown).
erg mutants of S. cerevisiae are susceptible to drugs. In order
to ascertain the physical state of the membrane, we used
steady-state fluorescence polarization to examine the mem-
brane order (fluidity) of erg2, erg3, erg4, and erg6 mutants and
the WT strain. A specific plasma membrane fluorescent probe,
DPH, was used for such measurements, as described earlier (1,
19). All the erg mutant strains showed decreases in fluores-
cence polarization, thus implying decreased membrane order
or enhanced fluidity of the membranes of these mutants com-
pared to that for the WT strain (Fig. 2A). However, we did not
observe any significant change in fluidity of the membrane of
the erg4 strain, which is probably because it mediates the final
step of ergosterol biosynthetic pathway in yeast. In the plasma
membrane of the erg4 mutant, ergosterol is completely re-
placed with ergosta-5,7,22,24(28)-tetraen-3
-ol, which is struc-
turally highly related to ergosterol and thus is able to com-
pletely compensate for it in the membrane (53).
Whether the enhanced membrane fluidity of erg mutants in
any way affects the drug susceptibilities of the mutant cells was
checked in the following experiments. Since there is no rec-
ommended protocol for testing of the drug susceptibilities of S.
cerevisiae cells, we simultaneously used three independent
methods (filter disk, spot, and microtiter plate assays) to ex-
amine the drug susceptibilities of the erg mutants (8, 36, 38). As
evident from the results of the filter disk assay (Fig. 3), all erg
mutants were highly sensitive to most of the drugs tested,
which was evident from the sizes of the zones of inhibition. The
drug sensitivity was further confirmed by the microtiter assay,
in which MIC80s of the drugs for the cells of the erg mutant
strains were lower than those for the WT cells (Fig. 4B). The
drug sensitivities tested by spot assays also revealed that the
mutant strains were generally sensitive to the drugs tested (Fig.
4A). Thus, the results from three independent drug suscepti-
bility tests led us to confirm the results of the resistance pro-
filing of the erg mutants. Notably, all erg mutant strains except
strain erg4 were highly resistant to FLC; strain erg4 was even
FIG. 2. (A) Steady-state fluorescence polarization measurements
(p value) in an S. cerevisiae WT strain and its erg mutants. Measure-
ments were carried out with intact cells by using DPH as the fluores-
cent probe at excitation and emission wavelengths of 360 and 450 nm,
respectively, as described in Materials and Methods. The values are
means 	 standard deviations (indicated by the bars) of three indepen-
dent experiments. (B) Extracellular R6G concentration measured in S.
cerevisiae WT and its erg mutants at 60-min interval. Deenergized yeast
cells were incubated with R6G for 1 h, after which the cells were
harvested and the extracellular concentration of R6G in the superna-
tant was determined spectrophotometrically by measuring the absor-
bance at 527 nm. The values are means 	 standard deviations (indi-
cated by the bars) of three independent experiments.
(C) Accumulation of [3H]FLC in deenergized S. cerevisiae WT and its
erg mutants at 60-min intervals. The values are means 	 standard
deviations (indicated by the bars) of three independent experiments.
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more susceptible than the WT (MIC80s, 1 g ml
1 for erg4
versus 4 g ml1 for the WT). By the disk assay, however, no
major differences in the FLC susceptibilities of erg4 and other
mutant cells were evident. This points out that sometimes the
MIC and the result of the filter disk assay may not match (10).
Since there was no significant difference between the growth of
the erg mutants and the WT cells (Fig. 1B), differences in
growth could not have contributed to the observed variations
in drug susceptibilities. The observed resistance of erg mutants
of S. cerevisiae to FLC needs special mention. While our ob-
FIG. 3. Drug resistance profiles of S. cerevisiae WT and erg mutants determined by filter disk assay as described in Materials and Methods. The
numbers on the right represent zones of inhibition measured from the zones shown on the left.
FIG. 4. Drug resistance profiles of S. cerevisiae WT and erg mutants determined by the spot assay (A) and the microtiter assay (B). (A) For the
spot assay, the yeast cells were grown overnight on YNB plates at 30°C. The cells were then suspended in normal saline to an OD600 of 0.01 (A600).
Five microliters of fivefold serial dilutions of each yeast culture was spotted onto YNB plates in the absence (control) and presence of the following
drugs: 4-NQO (0.02 g ml1), CYH (0.01 g ml1), PHE (2 g ml1), SMM (1 g ml1), FLC (8 g ml1), and MTX (1 g ml1). Growth
differences were recorded following incubation of the plates for 48 h at 30°C. Growth was not affected by the presence of the solvents used for the
drugs (B) The microtiter assay (MIC80) was done as described in Materials and Methods.
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servation is limited to the erg mutants of S. cerevisiae studied,
evidence suggests that mutations in ERG genes could also
affect azole sensitivity in C. albicans cells. The accumulation of
ergosta-7,22-dienol-3
-ol in an azole-resistant clinical isolate
of C. albicans has been attributed to the absence of ERG3
(5,6-desaturase) (21, 33, 35, 44). Additionally, the susceptibil-
ity patterns of erg mutants of Candida could be different. In the
present study we observed that the erg6 mutant of S. cerevisiae
is resistant to FLC, while Jensen-Pergakes et al. (18) showed
that a C. albicans strain with the same mutation has nearly
identical susceptibilities to FLC and other azoles.
Membrane lipid phase affects passive diffusion of drugs. In
order to test the possible influence of enhanced membrane
fluidity on the rate of drug import via passive diffusion, we first
excluded the contributions of efflux pumps, which could inter-
fere with diffusion measurements. This was achieved by energy
depletion of cells, wherein S. cerevisiae cells were aerated for
1 h in the presence of 5 mM 2-deoxy-D-glucose and 5 mM
2,4-dinitrophenol, which was sufficient to deplete most of the
intracellular ATP (data not shown) (51). The yeast cells were
then incubated in the presence of the fluorescent substrate
R6G as described in Materials and Methods. The drug diffu-
sion in energy-depleted cells was determined by measuring
absorbance changes in the R6G contents in the supernatant
withdrawn at different times. It is evident from Fig. 2B that
after 1 h of incubation in the presence of R6G, the superna-
tants of all the mutant strains showed low extracellular R6G
concentrations, implying increased entry (passive diffusion) of
the fluorophore into the cells. The enhanced accumulation of
[3H]FLC (Fig. 2C) in energy-depleted cells (diffusion) also
confirmed that erg mutants elicit high levels of diffusion. Thus,
the drug sensitivities of the erg mutants could be due at least in
part to an enhanced passive diffusion of the drugs, which is
influenced by the membrane lipid phase.
In vitro-induced changes in membrane fluidity do not affect
drug resistance. In order to further explore if the physical state
of membrane lipids can indeed influence the drug resistance of
yeast cells, we induced changes in the membrane fluidity by a
known membrane fluidizer, benzyl alcohol (BA) (46). The
addition of 5 to 20 mM BA led to a gradual increase in mem-
brane fluidity which was maximally enhanced to 10 to 12% in
cells exposed to 20 mM BA (Fig. 5). The enhanced fluidity also
led to an increase in the diffusion of R6G by 15%. However,
the BA-induced changes in fluidity and passive diffusion did
not alter the sensitivities to the drugs tested (data not shown).
It is thus probable that enhanced membrane fluidity and the
diffusion therefrom may not be the only cause of the hyper-
sensitivity observed for the erg mutants.
Membrane environment selectively affects drug extrusion
pumps of Candida when expressed in S. cerevisiae. In view of
the intricate relationship between the membrane lipid phase
and the membrane proteins, we examined the functioning of
two MDR pumps of C. albicans, Cdr1p and CaMdr1p, in an
altered membrane environment. Both the WT and erg mutants
of S. cerevisiae were transformed with the CDR1 and CaMDR1
genes cloned on an identical vector, as described in Materials
and Methods. The levels of expression of CDR1 and CaMDR1
were unaffected in erg mutants compared to the levels of ex-
pression in the WT strain (data not shown). The drug resis-
tance conferred by the levels of expression of these proteins in
an altered membrane environment was examined by a micro-
titer plate method (Fig. 6). Since erg mutant strains displayed
different levels of hypersensitivity to the drugs compared to the
sensitivity of the WT strain (Fig. 3 and 4), we calculated the
fold change (Fig. 6) in resistance of the yeast transformants
from that of their respective nontransformant strains. The
Cdr1p-mediated drug resistance appeared to be adversely af-
fected by the lipid environment. For example, the ability of
Cdr1p to mediate resistance to CYH (which is a preferred
substrate for this pump) was severely hampered (two- to four-
fold decrease), especially in the erg2, erg3, and erg6 mutant
backgrounds. The fold resistance to FLC by Cdr1p was also
decreased in the erg mutant strains, while the levels of resis-
tance to 4-NQO, MTX, SMM, and PHE remained unaffected
(Fig. 6). Interestingly, CaMdr1p appeared to be insensitive to
membrane alterations since the fold increase in resistance that
it mediated remained largely unchanged or increased between
the WT and its erg mutant strains (Fig. 6). The resistance to
FIG. 5. Measurement of membrane fluidity and passive diffusion of S. cerevisiae WT cells induced by BA. Fluidity was determined by measuring
the steady-state fluorescence polarization with DPH as the fluorescent probe as described in the legend for Fig. 2A. Diffusion was determined by
measuring the extracellular R6G concentration as described in the legend for Fig. 2B. The values are means 	 standard deviations (indicated by
the bars) of three independent experiments.
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FIG. 6. Graphical representations showing the fold increase in drug resistance of WT and erg mutant strains of S. cerevisiae upon transformation
with Cdr1p- and CaMdr1p-encoding plasmids (see Materials and Methods). The fold increase in resistance to each drug was calculated as the
difference in resistance between the nontransformant and transformant pair for each cell type. MTX is the substrate for CaMdr1p (24), and the
fold change in resistance is much higher for CaMDR1-transformed erg mutant cells than for CDR1-transformed erg mutant cells. Note the change
in the x axis for fold MTX resistance.
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FLC mediated by Cdr1p needs special mention. It is evident
from Fig. 3 and 4 that erg mutants are intrinsically resistant to
FLC. The WT strain, which was sensitive to FLC, exhibited a
16-fold higher level of resistance when CDR1 was expressed in
this background. On the other hand, expression of CaMDR1 in
the WT yeast strain resulted in only a fourfold enhanced level
of resistance. Interestingly, while the fold resistance to FLC is
more or less maintained in the case of CaMDR1 expression,
CDR1-transformed erg mutant cells could not sustain the level
of resistance elicited in WT cells.
Cdr1p is more sensitive to lipid environment. It became
clear from the results presented above that, compared to
CaMdr1p, which is an MFS transporter, ABC drug transporter
Cdr1p is more sensitive to lipid perturbations. In order to
explore such an interaction between membrane ergosterol and
sphingomyelin, we preformed the experiment described below.
We labeled WT and erg mutant cells of S. cerevisiae with
NBD-SM. The important advantage of this lipid analogue is
that it can readily be inserted into biological membranes by
spontaneous lipid transfer from exogenous carriers (20, 48). At
90 min postlabeling, when the level of NBD-SM incorporation
was maximal, the cells were washed and the associated
NBD-SM of the labeled cells was back extracted by using 2%
fatty acid-free BSA. The labeling protocol and back exchange
of labeled NBD-SM were described in Materials and Methods
and in an earlier publication (48). Figure 7B depicts the ex-
changeability of NBD-SM from different labeled strains of S.
cerevisiae. It is clear that the efficiency of extraction of
NBD-SM by BSA from erg mutants is greater than that from
the WT (Fig. 7B). It probably suggests that ergosterol deple-
tion in erg mutant cells results in disruption of the interaction
between ergosterol and sphingomyelin, which leads to the en-
hanced exchange of NBD-SM. In order to examine the lipid
interaction more closely, the growth media of erg mutants was
supplemented with ergosterol. That supplemented ergosterol
is incorporated into the membrane was confirmed by spectral
analysis. Figure 7A shows the appearance of characteristic
peaks of ergosterol in supplemented cells. Interestingly, the
exchange of NBD-SM was considerably reduced (restored to
the level for WT cells) when erg mutant cells were grown in
ergosterol-supplemented media (Fig. 7B). This shows that the
ergosterol content affects the exchangeability of sphingomyelin
and thus implies a close interaction between the two mem-
brane lipid components.
DISCUSSION
In this study we have presented evidence highlighting the
close interaction between membrane lipids and the drug sen-
sitivities of yeast cells. For this we used erg2, erg3, erg4, and erg6
mutants of S. cerevisiae which are blocked in late ergosterol
biosynthesis (Fig. 1A). Due to defective ergosterol biosynthesis
and, as a result, the accumulation of various intermediates,
these mutants possessed high levels of membrane fluidity.
These mutants were in general sensitive to several of the drugs
tested; however, they were resistant to FLC (the only azole
tested). The hypersensitivities of the yeast erg mutants could be
attributed to membrane permeability changes which may in-
volve changes in passive diffusion across the membrane or in
the active transport of these drugs. In support of the former,
Van Den Hazel et al. (51) have shown that the lack of PDR16
and PDR17 (which encode homologues of Sec14p) S. cerevisiae
cells results in altered phospholipid and sterol compositions
and renders cells hypersensitive to many drugs due to their
increased passive diffusion. In support of the latter possibility,
the ABC transporter Pdr5p has been shown to function less
efficiently in cells from which erg6 is deleted. A recent report by
Emter et al. (9), however, suggests that ERG6 of S. cerevisiae
increases the rate of passive drug diffusion without affecting
Pdr5p-mediated drug export. In this study we used two sub-
strates, i.e., the fluorophore R6G and radiolabeled FLC, and
observed that erg mutants elicited higher levels of passive dif-
fusion. This suggests that the enhanced diffusion of drugs could
contribute to the hypersensitivities of the erg mutants. How-
ever, in another set of experiments, when we increased the
membrane fluidity by using a membrane fluidizer, BA, we
observed that a 10 to 12% increment in fluidity did not affect
the susceptibilities of the S. cerevisae cells to the drugs tested.
Taken together, it appears that the change in membrane flu-
idity and the increased diffusion therefrom alone may not be
sufficient to result in the observed higher susceptibilities of the
erg mutants. Since these mutants have altered sterol composi-
tions, it is likely that sterol interactions with other membrane
lipids and transporters could be more relevant to the higher
drug susceptibilities observed.
We observed that when the MFS transporter CaMdr1p and
the ABC transporter Cdr1p of C. albicans are expressed in erg
mutants of S. cerevisiae, the latter appears to be more respon-
sive to the fluctuations in the membrane lipid environment. We
show that when Cdr1p is expressed in erg mutants it could not
restore the level of resistance to CYH and FLC compared to
the level of resistance obtained when it was expressed in WT
cells. Interestingly, two independent observations suggest that
drug extrusion pump sensitivity to the lipid environment was
not a general phenomenon: first, the Cdr1p-mediated levels of
resistance to drugs like NQO, SMM, PHE, and MTX re-
mained unchanged when Cdr1p was expressed in erg mutants,
while the sensitivities to CYH and FLC changed drastically;
second, the CaMdr1p-mediated levels of resistance to similar
drugs remained unaffected and were rather improved in some
instances when CaMdr1p was expressed in an erg background.
Taken together, our results suggest that the Cdr1p ABC drug
extrusion pump is selectively more sensitive to fluctuations in
sterol composition.
Human P-gp, a homologue of Cdr1p, is also shown to be
sensitive to fluctuations in the membrane lipid environment,
where it intimately interacts with membrane sphingomyelin
and cholesterol (32). In this study, we also observed a close
interaction between membrane sterol (ergosterol in this case)
and sphingolipids. We were able to exchange larger amounts of
NBD-SM from erg mutants which could be reversed if the
mutants were supplemented with ergosterol. A very recent (49)
report shows that regulation of sphingolipid metabolism is
sterol dependent in S. cerevisiae. This again signifies the mutual
importance of the two membrane lipids in yeast (4).
Interestingly, Cdr1p-mediated phospholipid translocase ac-
tivity was found to be independent of ergosterol depletion (47).
This shows how functional domains of a protein respond dif-
ferently to fluctuations in the lipid environment. Such selective
sensitivity of an efflux pump protein (Cdr1p) to fluctuations in
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the membrane lipid environment (loss of resistance to certain
drugs) and selectivity within the efflux proteins (Cdr1p is more
sensitive to lipid fluctuation than CaMdr1p) do point to very
specific interactions between efflux pump proteins and mem-
brane lipids.
Recently, Kontoyiannis (25) has provided genetic evidence
that Pdr5p-mediated resistance to FLC is altered in the back-
ground of mutations that affect ergosterol homeostasis. It is
suggested that the ABC protein functions in the maintenance
of ergosterol homeostasis by extrusion or transport of sterol
intermediates. In view of the observed close interaction
between ergosterol and sphingomyelins in the yeast mem-
brane, such homeostasis is expected to be perturbed in erg
mutants and could affect the functioning of drug extru-
sion pump proteins (14). That mitochondria and oxida-
tive phosphorylation are physiological partners of at
least Erg3p is another aspect which merits attention (26).
In view of the compelling evidence from various sources
in which differences in the membrane ultrastructures and
the sterol and phospholipid compositions between drug-resis-
tant and -sensitive cell lines (for a review, see reference 11)
and yeast cells (30) are observed, it is important to assess the
roles of such changes in the overall scenario of multidrug
resistance.
FIG. 7. (A) UV absorption spectra of sterols extracted from the S. cerevisiae WT strain and its erg mutants grown in the absence and in the
presence () of ergosterol. The cells were supplemented with 10 g of ergosterol ml1 and grown for 20 h at 30°C before lipid extraction. The
supplemented cells were harvested and washed thoroughly before extraction of sterols as described in Materials and Methods. The UV spectra
of WT cells were the same as those of the unsupplemented cells; hence, only one trace is shown in the first panel. (B) Postlabeling transbilayer
exchange of NBD-SM in the S. cerevisiae WT and its erg mutants. Cells were grown in the absence (open bar) and presence (filled bar) of
ergosterol-supplemented media as described in Materials and Methods. NBD-SM labeled cells were washed twice with buffer A and were then
incubated with 2% BSA to back exchange the NBD-SM from the labeled cells, as described in Materials and Methods. The percentage of total
extracted NBD-SM was calculated (according to the formula given in Materials and Methods). The graph presents data for the 90-min time point
during which the maximum back-exchanged fluorescence in the supernatant was observed. The values are the means 	 standard deviations
(indicated by the bars) of three independent experiments.
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